Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

FDA Approves Enhertu for HR-Positive, HER2-Low and HER2-Ultralow Metastatic Breast Cancer

CrisprBits Unveils State-of-the-Art CRISPR Gene Editing Lab in Bengaluru

Takara Bio Acquires Curio Bioscience, Advancing Leadership in Spatial Genomics

Tempus AI Launches FDA-Approved xT CDx for Comprehensive Solid Tumor Profiling

FDA Accepts Eisai’s Biologics License Application for LEQEMBI® Subcutaneous Autoinjector for Alzheimer’s Disease

Paige’s FullFocus™ Digital Pathology Viewer Receives FDA 510(k) Clearance for Expanded Compatibility

Grifols, MJFF Launch Chronos-PD to Identify Early Parkinson’s Biomarkers

Gates Foundation Invests $50M in Tessera’s In Vivo Gene-Editing Therapy for Sickle Cell Disease

GSK Acquires IDRx for $1 Billion to Advance Precision Therapy for GIST

Scipher Medicine and Roivant Partner to Advance Precision Medicine in Rheumatology

Home
/
update
/
details

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

NextEdge Admin

30 Jan 2025

2 min 41 sec

Merck KGaA,Colorectal cancer,RAS biomarker

Diatech Pharmacogenetics (Jesi, Italy) has expanded its collaboration with Merck Serono Middle East Ltd., affiliates of Merck KGaA, to enhance patient access to RAS biomarker testing in the Middle East and Africa (MEA) regions.

Colorectal cancer is the third most common cancer worldwide, accounting for 10% of cases and ranking as the second leading cause of cancer-related deaths. In 2020, an estimated 1.9 million new cases and over 930,000 deaths were reported. Incidence rates are highest in Europe, Australia, and New Zealand, while Eastern Europe records the highest mortality rates. By 2040, global colorectal cancer cases are expected to rise by 63% to 3.2 million annually, with deaths increasing by 73% to 1.6 million.

Targeted therapies combined with chemotherapy benefit patients with specific genetic mutations like KRAS, BRAF, and NRAS, while immunotherapy is effective for tumors exhibiting microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR).

Diatech Pharmacogenetics offers a CE IVD-certified diagnostic solution that delivers fast, precise biomarker results for colorectal cancer. The user-friendly, easy-to-install system integrates seamlessly into various laboratory environments with dedicated analysis software.

Oliva Alberti, CEO of Diatech Pharmacogenetics, stated: “We are excited to expand our partnership with Merck in the MEA region, ensuring timely and accurate genetic testing for metastatic colorectal cancer (mCRC) patients. This collaboration supports our mission to advance personalized medicine globally.”

Ramsey Morad, SVP & Head of MEAR at Merck, added: “Merck is committed to improving patient care by expanding access to innovative solutions. This collaboration strengthens our efforts in RAS biomarker testing, empowering healthcare providers to offer personalized treatment for colorectal cancer patients, ultimately improving outcomes across the MEA region.”